Correction: The association of osteoporosis and geriatric syndromes in the elderly: data from the Russian epidemiological study EVKALIPT

Dudinskaya, Е. N.; Vorobyeva, N. M.; Onuchina, Yu. S.; Matchekhina, L. V.; Селезнева, Е. В.; Овчарова, Лилия Николаевна; Kotovskaya, Yu. V.; Tkacheva, О. N.

doi:10.1007/s11657-023-01228-8

Arch Osteoporos

2023

DOI: 10.1007/s11657-023-01228-8

|View full text |Cite

Correction: The association of osteoporosis and geriatric syndromes in the elderly: data from the Russian epidemiological study EVKALIPT

Е. N. Dudinskaya

N. M. Vorobyeva

Yu. S. Onuchina

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Deprescribing bisphosphonates in the osteoporosis treatment in older people

Dudinskaya,

Malaya

2024

Osteopor Bone Dis

View full text Add to dashboard Cite

The term deprescribing (de-prescribe) means the abolition of appointments. In the modern researches, deprescribing is presented as a planned and controlled process of dose reduction or drug cessation, which can potentially harm the patient and/or does not benefit the patient. The target population for deprescribing is the older people, as old age and limited life expectancy are themselves reasons to try to reduce and optimize the drug load. Frailty syndrome or dementia, decreased kidney function and comorbidity are expected to coexist with polypragmasy and inconsistent appointments of different specialists. In foreign and domestic scientific studies there are manuals and recommendations on deprescribing of various groups of drugs for the elderly and seniors: proton pump inhibitors, sugary drugs, psychotropic drugs and others. However, with regard to osteoporosis drug therapy, the concept of deprescribing is debated rather sparingly, despite the possible serious side effects of osteoporosis treatment in the older age group.The review presents data from small clinical studies and systematic reviews describing deprescribing antiosteoporotic drugs from the bisphosphonate group, the reasons for their withdrawal and its consequences for the elderly and seniors with osteoporosis, as well as the analysis of tools for optimizing pharmacotherapy in elderly and seniors with respect to deprescribing of bisphosphonates.

show abstract

Deprescribing bisphosphonates in the osteoporosis treatment in older people

Dudinskaya,

Malaya

2024

Osteopor Bone Dis

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Correction: The association of osteoporosis and geriatric syndromes in the elderly: data from the Russian epidemiological study EVKALIPT

Cited by 1 publication

References 0 publications

Deprescribing bisphosphonates in the osteoporosis treatment in older people

Deprescribing bisphosphonates in the osteoporosis treatment in older people

Contact Info

Product

Resources

About